Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dual Glucose-dependent Insulinotropic Peptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonist in Women With Obesity for Frozen Embryo Transfer (FET): Pragmatic, Multicenter, Randomized Controlled Trial

NCT07811895 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT07811895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07811895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dual Glucose-dependent Insulinotropic Peptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonist in Women With Obesity for Frozen Embryo Transfer (FET): Pragmatic, Multicenter, Randomized Controlled Trial
Lead sponsor
RenJi Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
December 31, 2030
Enrollment
1,510 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

frozen embryo transfer, obesity, tirzepatide